Nitrosamine impurities continue to be a major focus for regulators—and in 2026, scrutiny is not slowing down.
The U.S. Food and Drug Administration has maintained strong oversight on nitrosamine risk across pharmaceutical products, particularly following past recalls involving widely used medications. What began as a targeted issue has now evolved into a long-term regulatory priority affecting drug development, manufacturing, and quality systems.
For pharmaceutical companies, nitrosamine control is no longer reactive—it is expected to be built into routine operations.
Why Nitrosamines Remain a Regulatory Priority
Nitrosamines are potentially carcinogenic impurities that can form during drug manufacturing or storage. Even at low levels, their presence raises concerns about patient safety.
Regulatory agencies have issued guidance requiring companies to proactively assess and mitigate the risk of nitrosamine formation across products and processes.
This includes evaluating:
- Raw materials and supplier inputs
- Manufacturing processes and chemical reactions
- Storage conditions and packaging
- Degradation pathways over time
The expectation is clear: organizations must fully understand and control impurity risks.
What FDA Inspectors Are Looking For
In 2026, FDA inspections are increasingly focused on how companies manage nitrosamine risk as part of their overall quality systems.
Key areas of focus include:
- Risk assessments, identifying potential sources of nitrosamine formation
- Analytical testing methods, ensuring accurate detection and quantification
- Process controls, preventing impurity formation during manufacturing
- Supplier oversight, confirming material quality and consistency
- Documentation and traceability, supporting decision-making and compliance
Inspectors expect these elements to be integrated into routine operations—not treated as isolated activities.
Ongoing Challenges for Industry
Despite increased awareness, many organizations continue to face challenges in managing nitrosamine risk.
These include complex chemical pathways, variability in raw materials, limitations in analytical detection, and evolving regulatory expectations.
In some cases, companies are still addressing legacy products that were not originally designed with these risks in mind.
Managing nitrosamines requires both technical expertise and strong quality system integration.
The Shift Toward Proactive Impurity Control
The industry is moving toward a more proactive approach, where impurity risk is considered early in product development and continuously monitored throughout the lifecycle.
This includes incorporating risk assessments into development, strengthening supplier qualification, and implementing robust analytical strategies.
Rather than responding to findings, organizations are expected to prevent them.
What This Means for Pharmaceutical Companies
Nitrosamine control is now a long-term regulatory expectation that impacts multiple functions, from R&D to manufacturing to quality assurance.
Companies must ensure that their systems are capable of identifying, assessing, and controlling impurity risks on an ongoing basis.
Failure to do so can result in product recalls, regulatory action, and reputational impact.
How EMMA International Supports Nitrosamine Risk Management
At EMMA International, we support organizations in assessing and mitigating nitrosamine risk across products and processes.
Our teams provide expertise in risk assessment, analytical strategy, manufacturing controls, and regulatory compliance to ensure alignment with FDA expectations.
As regulatory focus continues, organizations that integrate impurity control into their quality systems will be best positioned to maintain compliance and protect patient safety.
References
U.S. Food and Drug Administration. Control of Nitrosamine Impurities in Human Drugs Guidance.
European Medicines Agency (EMA). Nitrosamine Risk Assessment Guidance.
International Council for Harmonisation (ICH). Q3A and Q3B Impurities Guidelines.
